口服奈玛特韦与利托那韦组合用药治疗儿童新型冠状病毒肺炎3例  

COVID-19 treated with oral Nirmatrelvir-Ritonavir in 3 children

作　　者：石双 董娜 丁颖 王超[1] 袁浪 方永双 王冰洁 牛艳华 魏真真 蒲田 董晓艳 陆权 Shi Shuang;Dong Na;Ding Ying;Wang Chao;Yuan Lang;Fang Yongshuang;Wang Bingjie;Niu Yanhua;Wei Zhenzhen;Pu Tian;Dong Xiaoyan;Lu Quan(Department of Respiratory Medicine,Shanghai Children's Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200062,China)

机构地区：[1]上海市儿童医院,上海交通大学医学院附属儿童医院呼吸科,上海200062

出　　处：《中华儿科杂志》2022年第11期1168-1171,共4页Chinese Journal of Pediatrics

摘　　要：目的总结奈玛特韦与利托那韦组合用药(商品名Paxlovid)治疗儿童新型冠状病毒肺炎的经验及其临床效果。方法回顾性分析上海市儿童医院(上海市新型冠状病毒感染患儿定点医院)2022年5月1日至6月1日使用Paxlovid治疗的3例新型冠状病毒肺炎患儿的病例资料,分析临床表现及临床转归,动态监测血常规、肝功能、肾功能及新型冠状病毒核酸检测结果,观察用药期间相关不良反应等情况。结果3例患儿中男2例、女1例,分别为12、14、17岁。3例患儿均为存在基础疾病且有发展为重症新型冠状病毒肺炎风险的轻型病例,均有高热、咽痛及干咳等症状。3例患儿均在病程第3天予以Paxlovid口服,用药后1~2 d临床症状消失,2~4 d新型冠状病毒核酸检测转阴。其中1例用药期间出现少许皮疹,但停药后消退未再反复,3例均未见胃肠道,神经系统反应及肝、肾功能损伤。3例患儿在出院后3个月均未见新型冠状病毒肺炎后综合征相关临床表现。结论Paxlovid在3例儿童新型冠状病毒肺炎中的治疗有效且相对安全。Objective To summarize the application experience and the therapeutic effect of Nirmatrelvir-Ritonavir(trade name:Paxlovid)for COVID-19 in children.Methods A retrospective analysis was performed on the clinical data,including collecting the clinical manifestations and clinical outcomes,dynamically monitoring the blood routine,hepatic and renal function and SARS-CoV-2 nucleic acid results,and observing the related side effects during the treatment,etc,of 3 cases with COVID-19 treated with Paxlovid admitted to Shanghai Children's Hospital(designated referral hospital for SARS-CoV-2 infection in Shanghai)from May 1st to June 1st,2022.Results The 3 cases were 12,14,17 years of age,among which 2 cases were males,1 case was female.All 3 cases were mild cases with underlying diseases and risk of developing into severe COVID-19,with symptoms of high fever,sore throat and dry cough.The treatment of Paxlovid at 3rd day of symptom onset contributed to the symptom-free after 1-2 days and negative results of SARS-CoV-2 nucleic acid after 2-4 days.All patients had no adverse manifestations of gastrointestinal tract and nervous system but a case had little skin rashes,which recovered after the withdrawal of Paxlovid.Three cases had normal hepatic and renal function during the Paxlovid treatment.At 3 months after discharge,no clinical manifestations of post-COVID syndrome were found in all 3 cases.Conclusion Paxlovid was effective and relatively safe in the treatment of 3 children with COVID-19.

关 键 词：儿童 新型冠状病毒肺炎 奈玛特韦 利托那韦 

分 类 号：R725.6[医药卫生—儿科]